RxDoctor Payments Data

John McDonald

Gynecologic Oncology · Charlotte, NCNPI 1467496869

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,535 of the $10,637 with a category attached, or 99.0%. 4 manufacturers reported payments, led by GSK at 43.4% of the total. Reporting peaked in 2023 at $6,783 and has fallen 91.0% since, to $613 in 2024.

$10,637in general payments, 2019–2025

Across 9 payments — averaging $1181.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$5K
  • AstraZeneca$4K
  • Seagen Inc.$2K
  • Eisai Inc.$37
$133,132in research payments, 2019–2025

Across 11 payments — averaging $12,103 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$133K
  • Tesaro, Inc.$500

What the payments were for

  • Consulting fees$10,53599%
  • Food & beverage$370%
  • Education$651%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$4,615
AstraZeneca3$4,410
Seagen Inc.1$1,575
Eisai Inc.2$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,637 in reported general payments places this provider in the 80th percentile of 52 gynecologic oncology providers in North Carolina.

See all gynecologic oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$54,227
Medicare patients
84
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$71
Estradiol11$29

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →